Navigation Links
Gene therapy Beneficial in Parkinson's Disease

The initial studies of human gene therapy for Parkinson's disease has given the green signal to technique showing it to safe, and useful in reducing symptoms for patients,// according to the reports of two groups of researchers.

In the neuroscience meetings held yesterday and last week the researchers reported that each of the 24 patients who received therapy in the two separate trials received some benefit and none had significant side effects.

Katie Hood, deputy chief executive officer of the Michael J. Fox Foundation for Parkinson's Research said that gene therapy had a tarnished reputation because of problems encountered in trials against other diseases.

In 1999 the Food and Drug Administration temporarily halted gene therapy trials after an 18-year-old who was treated for a mild genetic disorder died after a violent reaction to the procedure. in 2005 trials were again brought to a standstill after three French children who was treated for inherited immuno- deficiency disease developed leukemia and one of them died.

Hood said, ``It's very encouraging that two companies were able to show benefits with no significant adverse effects. Safety is obviously the first hurdle."

Patients have been cautioned however against placing too much hope in the findings because Parkinson's studies have been infamous for showing placebo effects. Researchers say that only when the techniques are tested in controlled trials, which are now in the planning stages, can they determine whether the benefits are real, and long-lasting or not.

Each year around 100,000 Americans are affected by Parkinson’s each year, and is characterized by severe tremors and rigidity in the limbs with loss of muscle control. Its cause although unknown yet has been presumed to be the result of the death of brain cells that produces a neurotransmitter called dopamine. Dopamine plays a key role in transmitting commands from the brain's mu scle-control centers.

Same technology was used by both teams for performing gene therapy, wherein a desired gene is inserted into a common virus called adeno-associated virus, which is known to readily infect humans. This virus has never been shown to cause disease. The genes used by both teams were quite different.

The team, led by Dr. Matthew J During from the Weill Cornell Medical Center in New York, used a gene responsible for the synthesis of enzyme, glutamic acid decarboxylase. This enzyme in turn converts compounds in the cell into the neurotransmitter, GABA that controls muscle movements. Parkinson’s disease has been known to be deficient in GABA in the subthalamic nucleus part of the brain.

Although injecting GABA directly into the brain eases symptoms of the disease, the hormone is quickly cleared, which is therefore a limits its benefits. During's team injected one side of the brain of 12 patients with one of three different concentrations of the gene therapy agent.

All 12 patients were found to have an improvement of at least 25 percent on a conventional scoring system that assesses the severity of Parkinson's symptoms, nine of them showed an improvement of at least 37 percent, while five of them were seen to have an improvement between 40 percent and 65 percent. Moreover the patients have observed these benefits to persist for a year unlike the benefits from a placebo effect which are mostly transient.

During said that sophisticated imaging of the patients' brains showed an increase in metabolism on the side where gene therapy was performed, and the amount of increase correlated with the degree of improvement in symptoms.

Neurologix Inc. of Fort Lee, N.J., a company created by During and his colleagues to commercialize the technology are the manufacturers of the gene therapy agent. The study was funded by Neurologix.

The second study was led by Dr. William J. Marks Jr. of the University of California at San Francisco, Here the gene for growth factor, neurturin closely related to the better-known growth factor GDNF was used in the study. Injection of GDNF into the putamen section of the brain has been shown to possibly impede, and perhaps even reverse, the loss of dopamine-secreting cells.
NL
'"/>




Related medicine news :

1. Acupuncture May Help Chemotherapy Side Effects
2. Antioxidants protect health tissue in people undergoing radiation therapy.
3. Distraction therapy found very effective in postoperative patients
4. Acupuncture superseeds massage therapy for short term relief of pain
5. Ovarian cancer in relationship with Hormone therapy
6. New therapy better at increasing bone density
7. Gene therapy - Aim to improve blood flow
8. Gene therapy restores sight
9. Heat therapy relieves back pain
10. Radiotherapy helps in colon cancer
11. New therapy for pimples
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in healthcare ... Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during ... , The annual award competition recognizes editorial and design excellence across a range of ...
(Date:10/12/2017)... Wesley Chapel, FL (PRWEB) , ... October 12, 2017 , ... ... Chapel is holding a treadmill relay – Miles by Moonlight to raise money for ... by donating $300 or more. , Teams will work together to keep their ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy ... health literacy software tool, and the Cancer Patient Education Network (CPEN), an independent ... today announce a new strategic alliance. , As CPEN’s strategic partner, HLI ...
(Date:10/12/2017)... Miramar, FL (PRWEB) , ... October 12, 2017 ... ... is presenting the latest in wound care advancements to physician colleagues, skilled nursing ... lecture is titled, "Navigating the Treacherous Waters of Wound Care." , "At many ...
(Date:10/12/2017)... CHICAGO (PRWEB) , ... October ... ... innovator in life sciences content management, presents its enhanced Pepper Flow promotional ... Oct. 16 -18, 2017. Pepper Flow’s increased insight-driven capabilities help marketers streamline ...
Breaking Medicine News(10 mins):
(Date:9/18/2017)... 2017 EpiVax, Inc. ("EpiVax") a ... immune engineering, today announced a new NIH-funded ... ... and presents a challenge for traditional flu ... be effective. Using state-of-the-art bioinformatics and molecular modeling methods, ...
(Date:9/12/2017)... NEW YORK , Sept. 12, 2017   EcoVadis , the ... chains, has published the first annual edition of its Global CSR Risk ... 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings that analyzed nearly ... ... Performance Index ...
(Date:9/12/2017)... Sept. 12, 2017  ValGenesis Inc., the global ... is pleased to announce the appointment of Dr. ... its Board of Directors and Chairman of Advisory ... life science companies to manage their entire validation ... paper in this process. Furthermore, ValGenesis VLMS enables ...
Breaking Medicine Technology: